Momelotinib Therapy in Myelofibrosis: 6-Years Follow-up Data on Safety, Efficacy and the Impact of Mutations on Overall and Relapse-Free Survival

@inproceedings{Tefferi2016MomelotinibTI,
  title={Momelotinib Therapy in Myelofibrosis: 6-Years Follow-up Data on Safety, Efficacy and the Impact of Mutations on Overall and Relapse-Free Survival},
  author={Ayalew Tefferi and Daniela Barraco and Terra L. Lasho and Kebede H Begna and Aref Al-Kali and William J Hogan and Mark R Litzow and Curtis A. Hanson and Rhett P. Ketterling and Naseema Gangat and Animesh Pardanani},
  year={2016}
}
Background: Momelotinib is a JAK 1/2 inhibitor that is active in the treatment of myelofibrosis (MF); a previous phase 1/2 study included 100 consecutive patients from the Mayo Clinic (Leukemia. 2015;29:741). In the current long-term study of these 100 patients, we provide a cumulative account of short and long term efficacy and toxicity data, as well as survival analysis. Methods: The current study represents sponsor-independent analysis. The study patients are part of a larger (n=166) phase-1… CONTINUE READING

Topics from this paper.